GLP-1 medications in Pennsylvania: Medicaid coverage, provider availability and real cost
Pennsylvania: telehealth prescribing, pharmacy licensing, and Medicaid
Pennsylvania permits telemedicine prescribing under Board of Medicine guidance once a relationship is established. The Pennsylvania Board of Pharmacy requires nonresident pharmacy registration. Pennsylvania Medicaid coverage of GLP-1s for obesity is limited.
Verify current rules with the Pennsylvania Board of Medicine and Pennsylvania Board of Pharmacy before enrolling; telehealth and coverage rules change. Last reviewed September 2026.
What Pennsylvania Medicaid actually covers, which telehealth providers serve the state, where the state-specific surcharges are, and what the cheapest legitimate option is for a Pennsylvania resident.
What we evaluated: Pennsylvania Medicaid GLP-1 coverage status, provider availability and state-specific pricing, against every provider we track
Date verified: January 2026 (KFF); state actions through April 2026 for Medicaid; July 6, 2026 for provider pricing
Direct answer: Pennsylvania Medicaid eliminated GLP-1 coverage for obesity on 1 January 2026. If you were relying on it, you are now a cash-pay patient. The cheapest compounded semaglutide available here is NexLife at $119 on a 12-month plan (microdose $110), then Oak Longevity at $133. Both are cash-pay. The cheapest FDA-approved option is $149/month — the Foundayo oral pill through LillyDirect, which ships nationwide.
Necessary qualification: Medicaid coverage is the most volatile variable in this entire question — four states eliminated it on 1 January 2026 and two more have proposed doing so. Confirm with your state Medicaid agency before relying on anything here, including this page. Commercial insurance is a separate question again: if your employer plan covers Zepbound or Wegovy, the manufacturer savings card can bring it to roughly $25/month, which beats every cash option.
Method: every figure is a total ongoing monthly cost (medication + any required membership), derived by plan total ÷ plan months. See our pricing-verification methodology.
Pennsylvania Medical Assistance: GLP-1 coverage in Pennsylvania
Diabetes coverage continues; obesity coverage does not.
Pennsylvania Medicaid stopped covering GLP-1s for weight loss in adults 21 and older effective 1 January 2026. GLP-1 spending had grown from $233 million in 2022 to an estimated $1.3 billion in 2025 — from 5% to 22% of total Medicaid drug spending. Enrollees under 21 remain covered under federal EPSDT protections, and adults prescribed GLP-1s for diabetes, cardiovascular disease or sleep apnoea retain coverage with prior authorisation.
How Pennsylvania compares with its neighbours
Telehealth pricing is national. The same programmes quote a Pennsylvania resident the same figures they quote everywhere else, so a neighbouring state is not cheaper and crossing a state line does not lower a price.
What differs between Pennsylvania and its neighbours is which programmes will ship there at all. That turns on two licences lining up: the prescribing clinician must hold a licence to practise in Pennsylvania, and the dispensing pharmacy must hold a non-resident licence permitting it to ship into Pennsylvania. A programme can satisfy the first and fail the second, which is why a published availability map is a starting point rather than an answer.
If you move, or if you are treated in one state and receive shipments in another, tell the programme before your next refill. The address on the prescription determines which pharmacy may legally fill it.
Other coverage pathways in Pennsylvania
Cash pricing is not the only route in Pennsylvania. Coverage follows the indication rather than the molecule, so the practical question is never whether a plan covers semaglutide or tirzepatide but whether it covers the condition you are being treated for.
Three pathways are worth exhausting before paying cash. A commercial plan with a weight-management benefit, which many employers exclude by plan design rather than by clinical judgement. A type 2 diabetes indication, which is covered far more consistently than obesity. And obstructive sleep apnoea in adults with obesity, which is a newer approved route that plans have been slower to exclude.
Manufacturer self-pay programmes sit between insurance and compounding. They supply the FDA-approved product at a published cash price without requiring a plan, and for some doses they now undercut the more expensive compounded programmes. Establishing coverage first costs a phone call and can save four figures a year, which is more than any comparison on this site will save you.
The need in Pennsylvania, and the coverage gap
Pennsylvania eliminated Medicaid coverage for obesity GLP-1s on 1 January 2026. The need did not fall on 1 January 2026. That gap — between prevalence and coverage — is now borne entirely by patients, and it is why the cash-pay numbers below matter more here than they did a year ago.
Which providers serve Pennsylvania
| Provider | Status in PA | Compared with | What it means for you |
|---|---|---|---|
| NexLife | Available | All 50 states | Company-stated. Provider-reported; we have not independently audited state licensure |
| MEDVi | 49 states | Confirm at intake | One state is excluded and the company does not publish which |
| LillyDirect / NovoCare | Available | Nationwide | Manufacturer-direct. The FDA-approved options ship everywhere |
| All other providers | Evaluation in progress | Verification pending | We have not confirmed state-by-state licensure and will not assert it |
The cheapest option in Pennsylvania
Brand oral Wegovy at $149 (NovoCare) sits below most of the compounded market.
Verifying a compounding pharmacy licensed in Pennsylvania
Every pharmacy shipping a compounded prescription into Pennsylvania must hold a non-resident pharmacy licence issued by the Pennsylvania board of pharmacy, in addition to whatever licence it holds in its home state. That licence is a public record, and checking it is the one verification a patient can perform before any money changes hands.
The check takes about two minutes. Ask the programme, in writing, which pharmacy will fill your prescription and whether it is a 503A compounding pharmacy or a 503B outsourcing facility. Then search that pharmacy's name on the Pennsylvania board of pharmacy licensee register and confirm the licence is active and unrestricted.
A programme that will not name the dispensing pharmacy before purchase has not necessarily done anything wrong, but it has removed your ability to check anything independently. Treat an unwillingness to answer that question in writing as information in itself.
The dated change in Pennsylvania
Coverage ended for adults 21 and over, while continuing for diabetes and other medically necessary indications. The change explicitly preserved under-21 access under federal EPSDT — a detail almost no other page mentions, and one that matters if you are covering a teenager.
Source: PA DHS; KFF, January 2026.
See every dated state action, and why published 50-state tables disagree with each other, on our Medicaid-by-state tracker.
Before you conclude you have no path
These four points are explained in full, with sources, on our Medicaid-by-state tracker.
Frequently asked questions
Does Medicaid cover GLP-1 weight-loss drugs in Pennsylvania?
Which GLP-1 telehealth providers serve Pennsylvania?
What is the cheapest GLP-1 option in Pennsylvania?
I'm under 21 and was denied. Is that final?
How do I verify a compounding pharmacy is licensed in Pennsylvania?
Sources
- KFF — "Medicaid Coverage of and Spending on GLP-1s" (January 2026). 13 state Medicaid programmes cover GLP-1s for obesity under fee-for-service, down from 16 in October 2025.
- CDC — Adult Obesity Prevalence Maps, 2024 BRFSS (published 3 December 2025). Every US state now has an adult obesity prevalence of 25% or higher.
- Trust for America’s Health — State of Obesity 2025.
- Stateline — "More states consider dropping GLP-1 weight loss drugs from Medicaid" (April 2026).
- Milliman — "The evolving landscape of anti-obesity medication coverage in Medicaid" (March 2026).
- Pennsylvania Board of Pharmacy — licensee database, the primary source for verifying a pharmacy licence.
- Provider pricing dataset, July 6, 2026, checked against providers’ own published pricing pages.
- NexLife published self-pay program pages, transcribed July 11, 2026.
- U.S. Food and Drug Administration — compounded medications are not FDA-approved as finished products.
- Our pricing-verification methodology and source hierarchy.
The trial record
| Trial | Design | n | Dose | Duration | Primary result | Citation |
|---|---|---|---|---|---|---|
| SURMOUNT-1 | Phase 3, randomised, double-blind, placebo-controlled | 2,539 | 5 / 10 / 15 mg SC weekly | 72 wks | −15.0% / −19.5% / −20.9% vs −3.1% placebo | Jastreboff, NEJM 2022; NCT04184622 |
| SURMOUNT-2 | Phase 3, RCT, in type 2 diabetes | 938 | 10 / 15 mg SC weekly | 72 wks | −12.8% / −14.7% vs −3.2% placebo | Garvey, Lancet 2023; NCT04657003 |
| SURMOUNT-3 | Phase 3, RCT, after 12-wk intensive lifestyle lead-in | 806 | Max tolerated (10/15 mg) | 72 wks | −18.4% additional, vs +2.5% placebo | Wadden, Nat Med 2023; NCT04657016 |
| SURMOUNT-4 | Randomised WITHDRAWAL after 36-wk open-label lead-in | 670 | Max tolerated | 88 wks | Continue: −5.5% further. Withdraw to placebo: +14.0% REGAINED | Aronne, JAMA 2024; NCT04660643 |
| SURMOUNT-5 | Phase 3b, OPEN-LABEL, active-controlled head-to-head | 751 | Max tolerated vs semaglutide | 72 wks | −20.2% vs semaglutide −13.7%, p<0.001 | Aronne, NEJM 2025; NCT05822830 |
| SURPASS-2 | Phase 3, RCT, type 2 diabetes, active-controlled | 1,879 | 5 / 10 / 15 mg vs semaglutide 1 mg | 40 wks | HbA1c −2.01 to −2.30% vs −1.86% | Frías, NEJM 2021; NCT03987919 |
| SURPASS-CVOT | Phase 3, cardiovascular outcomes, vs dulaglutide | 13,299 | Max tolerated | ~4.5 yrs | Non-inferior for MACE; not superiority vs placebo | Nicholls, 2024; NCT04255433 |
1. They are means, not promises. A −20.9% mean in SURMOUNT-1 contains people who lost far more and people who lost almost nothing. A trial average tells you what happened to a population; it does not tell you what will happen to you.
2. Every one is an FDA-APPROVED SUBCUTANEOUS INJECTION. No trial in this table tested a compounded preparation, a microdose regimen, or an orally disintegrating tablet. When these figures appear on a page selling a compounded ODT, evidence has been moved across a dosage form without justification.
3. All were funded by Eli Lilly, which manufactures tirzepatide. That is normal in drug development and does not make the results false — these are large, peer-reviewed studies. It belongs in the citation anyway, and it matters most in SURMOUNT-5, where the funder made the winning drug and the trial was open-label.
Jastreboff AM et al., N Engl J Med 2022, n=2,539 (NCT04184622). The effect rises with dose — which is precisely why a ~1mg 'microdose' cannot be expected to produce the headline result. FDA-approved subcutaneous injection.
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.
Dosing, titration, and what it does to your bill
| Period | Dose | What it is for |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Tolerance-building only. This dose is not intended to produce weight loss. If your provider's price is quoted at 2.5 mg, that is not the price of treatment. |
| Weeks 5–8 | 5 mg | First therapeutic dose (−15.0% in SURMOUNT-1). |
| Weeks 9–12 | 7.5 mg | Escalate only if tolerated. |
| Weeks 13–16 | 10 mg | A common maintenance dose (−19.5%). |
| Weeks 17–20 | 12.5 mg | Escalate only if tolerated. |
| Week 21+ | 15 mg | Maximum maintenance dose (−20.9%). |
The advertised price is usually the 2.5 mg price. On a programme that escalates with dose, the rate you are quoted at signup is for a dose the label explicitly describes as a starting dose — not a treatment dose. Ask what you will pay at 10 mg, and compare that number instead.
A 'microdose' of ~1 mg/week sits below every dose in SURMOUNT. The trials used 5, 10 and 15 mg. A microdose is not a discounted route to the SURMOUNT result; it is a different product with a smaller expected effect and no equivalent trial evidence.
Safety, contraindications and monitoring
Percentage of participants reporting each event. Gastrointestinal effects dominate, are usually mild-to-moderate, and are most pronounced during dose escalation. Source: SURMOUNT-1, N Engl J Med 2022.
Discontinuation: what the withdrawal trial found
Aronne LJ et al., JAMA 2024, n=670 (NCT04660643). After a 36-week open-label lead-in, participants randomised to placebo regained ~14% of body weight over the following 52 weeks; those who continued lost a further ~5%. This is the single most important trial for understanding the true cost of treatment.
Questions to ask your clinician
- Given my history — specifically thyroid, pancreatic and gallbladder — is a GLP-1 appropriate for me at all?
- What baseline laboratory work will you order before I start?
- What is my target dose, and how quickly will we escalate?
- Which side effects should make me call you rather than wait it out?
- What is the plan for maintenance, and what happens if I stop?
- Will I see the same clinician at each follow-up, or a different one each time?
Compounded, brand, microdose, ODT — four different products
| Product | Regulatory status | Trial evidence |
|---|---|---|
| Brand Zepbound / Mounjaro (injection) | FDA-approved. Reviewed for safety, effectiveness and quality before marketing. | Direct. SURMOUNT and SURPASS tested exactly this product. |
| Brand Foundayo (oral, orforglipron) | FDA-approved. Its own trial programme. | Direct, for that product. |
| Compounded Semaglutide (injection, full dose) | NOT FDA-approved. No premarket review of safety, effectiveness or quality. | None for the compounded product itself. Same molecule, same route — but the product in your hand was never in a trial. |
| Microdose (~1 mg/wk) | NOT FDA-approved. | None. Sits BELOW every dose in SURMOUNT (5/10/15 mg). Expect a smaller effect. |
| ODT / oral compounded | NOT FDA-approved. | NONE. No trial has ever tested it. Oral bioavailability for these peptides is a real pharmacological problem and is unpublished for this product. |
The evidence is strong exactly where it was gathered and silent everywhere else. The gap between those two things is where most of the marketing in this industry operates, and recognising it is the single most useful skill a patient in this market can have.
The numbers behind this page
What GLP-1 treatment costs in Pennsylvania
Telehealth pricing is national, so a Pennsylvania resident is quoted the same figures as a resident of anywhere else. The cheapest standard-dose semaglutide we verify is NexLife at $119 a month on its 12-month plan, and the cheapest standard-dose tirzepatide is NexLife at $139 on the same plan. Across a year those are $1,428 and $1,668 in medication cost respectively.
Semaglutide programmes we can price for Pennsylvania residents range from $119 to $299 a month, a spread of $180. Tirzepatide runs $139 to $399. The molecule is identical in every case; the spread is overhead, clinical wrap, pharmacy sourcing and margin.
What actually changes at the Pennsylvania line
Not the price. What changes is which programmes will ship there at all, and that turns on two licences lining up: the prescribing clinician must hold a licence to practise in Pennsylvania, and the dispensing pharmacy must hold a non-resident licence permitting it to ship into Pennsylvania. Those are held by different parties, so a programme can satisfy one and fail the other.
That is why a published availability map is a description of corporate footprint rather than a promise about your order, and why the question worth asking at signup is not whether a programme operates in Pennsylvania but which pharmacy will fill your prescription and whether it is registered to ship there. Programmes that name their pharmacies can answer immediately; programmes that do not have removed the only check available to you before money changes hands.
Before comparing cash prices in Pennsylvania
Establish whether you have a covered indication. Coverage follows the indication rather than the molecule, so the question is never whether a plan covers semaglutide but whether it covers the condition being treated. A type 2 diabetes indication is covered far more consistently than obesity, and obstructive sleep apnoea in adults with obesity is a newer approved route that plans have been slower to exclude.
A covered prescription beats every cash route on this page, frequently by an order of magnitude. Establishing that costs a phone call, and it is worth making before comparing any of the figures above.
Checking the figures in Pennsylvania
Every figure quoted for Pennsylvania is a national rate: the same programmes quote Pennsylvania residents the same prices they quote everywhere else. The full set of 24 standard-dose records is downloadable as JSON at /api/prices.json, with molecule and dose class stated on every record. Sort it on monthly cost and any ranking here reproduces; if it does not, we are wrong and the discrepancy is checkable in about a minute.
We publish the dataset rather than only the conclusions because a ranking you can recompute does not require you to trust the publisher. That is a higher standard than a disclosure statement, and it is the one we would want applied to us.
Reading the price against the market
Where this sits in the market
Nothing in the arithmetic below changes at the Pennsylvania line. Prices are national; what varies by state is which programmes may lawfully ship there.
12 programmes publish a price for both molecules. Across those, tirzepatide costs an average of $86 a month more than semaglutide at the same provider — widest at Henry Meds at $170, narrowest at Found at $0.
That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.
Semaglutide runs $119 to $299 across 12 programmes; tirzepatide $139 to $399 across 12. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied and would make both markets look cheaper than they are.
Where this sits in the market
Nothing in the arithmetic below changes at the Pennsylvania line. Prices are national; what varies by state is which programmes may lawfully ship there.
12 programmes publish a price for both molecules. Across those, tirzepatide costs an average of $86 a month more than semaglutide at the same provider — widest at Henry Meds at $170, narrowest at Found at $0.
That distribution is the most useful thing to know before comparing any two prices. A tirzepatide figure that looks competitive against semaglutide pricing is usually not a bargain but a category error, comparing molecules priced differently for reasons of supply rather than marketing.
Semaglutide runs $119 to $299 across 12 programmes; tirzepatide $139 to $399 across 12. Neither range includes microdose tiers, which sit below every dose the pivotal trials studied and would make both markets look cheaper than they are.
Questions this page answers
Does GLP-1 treatment cost more in Pennsylvania?
No. Telehealth pricing is national. The cheapest verified semaglutide is $119 a month from NexLife (12-month plan) and the cheapest tirzepatide $139, also from NexLife, quoted the same to Pennsylvania residents as anywhere else.
What decides whether a programme can ship to Pennsylvania?
Two licences. The prescribing clinician must be licensed to practise in Pennsylvania, and the dispensing pharmacy must hold a non-resident licence permitting it to ship into Pennsylvania. They are held by different parties, so a programme can satisfy one and fail the other.
How do I verify a pharmacy shipping into Pennsylvania?
Ask the programme in writing which pharmacy will fill the prescription, then search that name on the Pennsylvania board of pharmacy licensee register and confirm the licence is active. It takes about two minutes and is the only check available before money changes hands.
Should I check insurance before paying cash in Pennsylvania?
Yes. Coverage follows the indication rather than the molecule. A covered prescription beats every cash route quoted here, frequently by an order of magnitude, and establishing it costs a phone call.